Table 8.
Effect of GlucoMedix® on glucose concentrations in alloxan-induced hyperglycemic rats
| Group/dose (mg/kg) | Glucose (mg/dl) | |||||
|---|---|---|---|---|---|---|
| BASAL | 0 days | 7 days | 14 days | 21 days | 28 days | |
| Control (uninduced) | 89.0 ± 2.90 | 110.2 ± 5.53 | 106.6 ± 8.50 | 109.2 ± 8.63 | 112.6 ± 6.95 | 114.8 ± 6.05 |
| Negative Control (induced) | 90.2 ± 3.19 | 392.8 ± 18.62** | 419.8 ± 15.99** | 447.6 ± 15.85** | 465.4 ± 9.81** | 482.8 ± 2.59 ** |
| Glibenclamide 10 | 88.6 ± 3.36 | 347.2 ± 28.80** | 233.8 ± 14.72* | 166.8 ± 14.17*&& | 126.6 ± 15.19 && | 94.2 ± 5.45 *&& |
| GlucoMedix 250 | 90.4 ± 1.85 | 363.4 ± 28.75** | 340.8 ± 26.90**& | 318.4 ± 18.03**& | 292.6 ± 38.49*& | 248.8 ± 26.68 **& |
| GlucoMedix 500 | 95.8 ± 3.43 | 413.0 ± 14.75** | 390.6 ± 14.11** | 333.8 ± 11.50**& | 257.4 ± 15.59*& | 164.6 ± 9.77 *&& |
| GlucoMedix 1000 | 90.6 ± 3.65 | 349.8 ± 25.04** | 281.4 ± 14.96*& | 228.0 ± 8.03*& | 169.4 ± 10.29*& | 105.2 ± 4.15 *&& |
Values are expressed as mean ± SD. n = 7. * p < 0.05, ** p < 0.001 compared to control group; & p < 0.05, && p < 0.001 compared to negative control